Keywords: Pfizer, Neurontin, Epilepsy, NEJM, Marketing, Off-label use
Pfizer disputes NEJM findings of skewing data on Neurontin
Article | 12 November 2009
The world’s largest drugmaker, USA-based Pfizer, denies that it may have altered or omitted unfavorable study results relating to potential expanded uses of Neurontin (gabapentin), indicating the medicine worked better than internal company documents showed, as alleged in a report published in the New England Journal of Medicine yesterday.
Researchers from the University of California at San Francisco and the Johns Hopkins Bloomberg School of Public Health, say trials of Pfizer’s Neurontin epilepsy treatment for uses that were not yet approved may have been skewed to emphasize favorable results. Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.
FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!
Sign up in less than 60 seconds...no payment needed
Want to read the full article?
Take a 30 day FREE Trial worth £60
Take a no obligations 30 day trial.
Only one trial per user. Find out more details
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Pfizer acts to stop Mylan marketing generic Chantix; Allergan in $600 million settlement over Botox marketing practices
- PDL BioPharma sues Roche’s Genentech over royalties
- Novartis/NIH-sponsored research yields promising malaria drug candidate
- Indian’s Ranbaxy inaugurates new $30 million drug manufacturing facility in South Africa
- Seattle Genetics gets milestone as Astellas unit moves cancer drug into Ph I
